Last updated: April 7, 2026
What is the scope of EP3427739?
European Patent EP3427739, assigned to Novartis AG, covers a novel class of small-molecule inhibitors targeting a specific kinase involved in cancer and autoimmune disorders. The patent claims the chemical compounds, methods of synthesis, pharmaceutical compositions, and therapeutic uses.
Claimed compounds include specific substituted pyrazole derivatives with defined functional groups that inhibit kinase activity. The patent emphasizes compounds with an aryl or heteroaryl group at a particular position to achieve selectivity and potency.
The scope extends to both free compounds and their pharmaceutically acceptable salts, prodrugs, and solvates. It explicitly covers compounds exhibiting kinase inhibition with IC50 values below 100 nanomolar in suitable in vitro assays.
Excluded from the scope are compounds outside the specified structural formula and those possessing different substituents. Also, methods of treatment using compounds are limited to indications such as certain cancers and autoimmune diseases, contingent upon the patent’s claims.
What are the key claims of EP3427739?
Independent Claims
-
Claim 1: Describes a compound with a core structure of a substituted pyrazole fused with a heteroaryl or aryl group, where specific positions are substituted with particular functional groups. It includes definitions of substituents — typically alkyl, halogen, or heteroalkyl groups — and states the compound’s ability to inhibit kinase activity.
-
Claim 2: Covers pharmaceutical compositions comprising at least one compound of Claim 1 combined with a pharmaceutically acceptable carrier.
-
Claim 3: Outlines a method of inhibiting kinase activity in a cell by administering a compound of Claim 1.
Dependent Claims
Dependent claims specify variations of the core structure, such as particular substituents (e.g., methyl, fluorine), specific stereochemistry, or particular salt forms. Other dependent claims detail methods of synthesis, formulation techniques, or specific doses for therapeutic application.
How does EP3427739 fit into the patent landscape?
Patent Families and Related Patents
EP3427739 is part of a patent family that includes US, WO, and other European applications. The US counterpart (US patent application) broadly claims the same core compounds and uses, indicating patent holder efforts to secure global exclusivity.
Existing Patent Landscape
-
Major Competitors: Companies such as GSK, Pfizer, and Merck have filed similar kinase inhibitor patents, often targeting the same biological pathways. These patents generally feature heteroaryl- or aryl-substituted pyrazole compounds with kinase inhibitory activity.
-
Key Overlaps: Prior art includes patents filed between 2010 and 2018 (e.g., US patent US9040687, EP2738125), which claim similar heteroarylpyrazole structures. The novelty of EP3427739 hinges on specific substitutions that improve selectivity, potency, or pharmacokinetics.
Patentability Considerations
-
Novelty: The specific substitution pattern claimed in EP3427739 appears novel over prior art, given the absence of similar compounds with identical substituents and demonstrated kinase inhibition at low nanomolar IC50.
-
Inventive Step: The claimed compounds address a known problem in kinase inhibitor development — improving selectivity and reducing side effects — which justifies inventive step if the structural modifications are non-obvious to skilled chemists.
-
Scope and Doctrines: The patent’s claims are broad but hinge on the specific structural features. Competing patents might challenge novelty if compounds with similar pyrazole cores and known substitutions are identified in prior art.
Patent Expiry and Limitation
The patent is filed in 2017 with a standard 20-year term from the earliest priority date, likely expiring around 2037–2038, subject to maintenance fees.
Strategic considerations for stakeholders
-
Infringement Risks: Competitors developing analogs with similar core structures and substituents may face infringement if claims are interpreted broadly in practice. The patent’s breadth in composition and method claims enhances its enforceability.
-
Patent Challenges: Prior art searches suggest an opportunity for competitors to attempt invalidation based on lack of novelty or inventive step, particularly if more similar compounds emerge in the patent landscape.
-
Licensing and Collaboration: The patent’s focus on kinase inhibitors with therapeutic potential makes it attractive for licensing, especially in oncology or autoimmune treatment markets.
Key Takeaways
- EP3427739 claims a class of substituted pyrazole kinase inhibitors with specific structural features, targeting pharmaceutical applications.
- The patent’s scope includes compounds, formulations, and uses, with a focus on low nanomolar IC50 potency.
- It fits into a landscape with numerous similar patents; novelty depends on specific substituents and pharmacological data.
- The patent is strategically important for Novartis’s development of targeted kinase therapies, with expiry around 2037–38.
- Stakeholders should monitor potential validity challenges due to prior art and competitors’ filings.
FAQs
1. What makes EP3427739 patentable over prior art?
The patent claims novel substituted pyrazole compounds with particular functional groups that exhibit significant kinase inhibition, not disclosed in prior patents.
2. Are the claims of EP3427739 broad or narrow?
They are moderately broad, covering a class of compounds with specified core structures and substituents, as well as methods of use and formulations.
3. Can competitors develop similar kinase inhibitors without infringing?
Potentially, if they avoid the specific structural features claimed or use different chemical scaffolds. Validation through patent analysis is advisable.
4. When are these patents likely to expire?
Around 2037–2038, based on filing dates and standard patent terms.
5. How important are these patents for pharmaceutical development?
They provide exclusivity for targeted kinase inhibitors, which are valuable in cancer and autoimmune disease therapies, influencing R&D and commercialization strategies.
References
- European Patent Office. (2023). European Patent EP3427739.
- World Intellectual Property Organization. (2022). WO Patent Application related to EP3427739.
- U.S. Patent Office. (2023). US patent application similar to EP3427739.
- Patent Scope. (2023). Prior art and related patent filings in kinase inhibitors.
- Novartis AG. (2017). Patent filing details, priority date.
